BioLineRx is trading 12.2% up at $2.30, with no confirmed catalyst identified for the October 16, 2026 move.
- The company's investor-relations page lists October 8 as its latest press release; the biotech ETF is down 2.06%, which does not explain the gain.
- A patent-allowance headline in search results dates to October 16, 2024, not October 16, 2026, so it is not a new catalyst.
- No reliable current-session trading-volume figure was found.